Core Insights - The 1RF brain ablation system has experienced significant adoption, with nearly 50% of all historical ablations occurring in the first fiscal quarter of 2026 [1] - The 1RF trigeminal nerve ablation system has entered a limited commercial launch, showcasing a competitive edge by requiring only a single probe placement compared to traditional systems that require multiple placements [1] - Management has accelerated the drug delivery program by approximately six months, with devices expected to be available for investigational or animal studies in Q3 fiscal 2026 [1] - The company is reinforcing its strategic positioning by forming an oncology advisory board to guide the application of delivery systems for challenging brain tumors such as glioblastomas [1] - The company is leveraging its existing 1RF and sEEG probe technology to expand into the lower back pain market through a basivertebral nerve ablation system [1] - Revenue growth of 5.5% sequentially indicates a transition from initial large-scale stocking orders to a steady-state replenishment cycle driven by market utilization [1]